Grifols, S.A. (GRFS) vs Medicus Pharma Ltd (MDCX)

Grifols, S.A. and Medicus Pharma Ltd are both Drug Manufacturers General companies. Grifols, S.A. is the larger, with a market value of $1.9B against $10.0M — 185.4× the size. Medicus Pharma Ltd has negative trailing earnings, so its P/E is not meaningful; Grifols, S.A. trades at 8.1×. Grifols, S.A. has the higher net margin (5.54% vs 0.00%) and the higher return on invested capital (0.00% vs −2,497.5%). Across the 11 metrics below, Grifols, S.A. leads on 9 and Medicus Pharma Ltd on 2.

Valuation

Metric GRFS MDCX Drug Manufacturers General median
P/E 8.14 n/m 24.72
P/S 0.58 n/m 3.35
P/B 0.54 n/m 5.00
Price to free cash flow 6.76 n/m 17.68
EV/EBITDA 7.80 n/m 13.91
EV/Sales 1.75 n/m 3.95
Earnings yield 12.29% (1,640.00%) 2.92%
Free cash flow yield 14.79% (355.04%) 4.42%

Profitability

Metric GRFS MDCX Drug Manufacturers General median
Gross margin 37.45% — 72.77%
Operating margin 16.43% 0.00% 18.90%
Net margin 5.54% 0.00% 8.27%
Free cash flow margin 0.00% 0.00% 17.25%
Return on equity 0.00% (7,441.07%) 6.97%
Return on assets 0.00% (290.34%) 2.76%
Return on invested capital 0.00% (2,497.51%) 6.30%

Growth

Metric GRFS MDCX Drug Manufacturers General median
Revenue growth (TTM) 16.03% — 6.79%
EPS growth (last fiscal year) 168.00% (136.21%) —
Revenue growth, 5-year CAGR 7.84% — 3.98%
Net income growth, 5-year CAGR 15.29% — 0.42%

Health

Metric GRFS MDCX Drug Manufacturers General median
Debt to equity 1.17 (10.42) 0.63
Current ratio 2.37 1.57 1.32
Net debt to EBITDA 5.19 0.25 1.15

Dividend

Metric GRFS MDCX Drug Manufacturers General median
Dividend yield 0.15% — 3.57%
Payout ratio 0.00 — 0.53

Size

Metric GRFS MDCX Drug Manufacturers General median
Market cap 1.86b 10.03m 125.91b

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack